10xBio Completes Series B Financing

August 23, 2021

SAN DIEGO (August 23, 2021) – 10xBio, LLC, a privately-held biotechnology company, completed a Series B financing from a select group of partners and private investors. Capital raised totaled approximately $2,470,000. Proceeds will be used to advance the company’s lead asset, 10XB101, into Phase 2 testing. The company anticipates the completion Phase 2 testing by Q4 of 2023.

John Dobak, M.D., the company’s Managing Director and Chairman commented, “We would like to thank our investors and partners that participated in this round, and we look forward to commencing Phase 2 development of 10XB101. This financing, combined with the proceeds from our licensing deal with Hugel, Inc., will allow us to complete a 2b study in submental contouring and a proof-of-concept study in lateral abdomen (flank) body contouring.”

About 10xBio
We are biotechnology company that focuses on new uses for existing therapies and technologies. This strategy allows us to build on existing safety profiles and leverage known mechanisms of action, resulting in a streamlined development and regulatory process. Our most advanced asset, 10XB101, is a pharmaceutical product that addresses unmet needs in dermatologic medicine.  For more information, visit us at

10xBio, LLC.
John Dobak, M.D.